Constitution and Validation of a New Symptom Assessment Tool for Overactive Bladder: Marmara Overactive Bladder Questionnaire (M–OBQ)

What's known on the subject? and What does the study add?

The linguistically validated Turkish version of OAB- V8 questionnaire that involves the first 8 questions of the original OAB form is being used since 2006 in our country. The reliability analysis of this form was performed by our group recently. Although the currently used Turkish version of OAB- V8 questionnaire is the best available symptom assessment tool to be used in patients with OAB, it does not allow us to question the quality of life and sexual effects of the disease.

ABSTRACT

Objective
The aim of this study is to constitute and validate a symptom questionnaire to be used in the diagnosis and follow up of patients with OAB that complies with the specific needs of the Turkish society and that allows the assessment of both disease symptoms and their effects on quality of life.

Materials and Methods
A total of 78 OAB patients and 90 control patients were included in this study between January 2007 and June 2007. All included patients underwent urine analysis/culture, blood creatinine levels, 3-day voiding dairy, urinary ultrasonography and plain abdominal graphy evaluations.

Results
Among 168 patients included 99 (58, 95) were males and 69 (41,1%) were females. Mean age was 47,3 (±17,2) years. Cronbach alpha value which is a determinant of internal consistency was 0.92 for M-OBQ questionnaire. The Spearman correlation co-efficient for total score was found to be 0.98 (p=0.001) in the test- retest analysis. The highest sensitivity (97%) and specificity (94%) values for the M-OAB questionnaire to make a diagnosis of OAB were obtained with a cut off value of 12.5 for the total score.

Conclusion
This study shows the development of a reliable and valid OAB specific symptom and quality of assessment tool that is short and easily applicable in the daily clinical practice. This questionnaire can provide the clinicians with practical comfort and a standardized quantification of the patient symptoms.

Key Words
Overactive bladder, symptom questionnaire, validation, quality of life

ÖZET
Amaç
Aşırı aktif mesane (AAM) hastalarının tanı ve izlemelerinde kullanılabilcek, hastalığın semptomlarını ve hayat kalitesine etkilerini aynı anda sorulayabilen, Türk toplumunun kendi özellikleriyle uygun bir sorgulama formunun oluşturulması amaçlanmıştır.

Gereç ve Yöntem
Ocak 2007–Haziran 2007 tarihleri arasında AAM tanısı ile takip edilen 78 hasta ve şıkayeti olmayan 90 hasta çalışmaya dahil edildi. Çalışmaya dahil edilen hastaların her birinin idrar tahlili, kan kreatinin ölçümü, 3 günlük işeme günlüğü, üriner sistem ultrasonografisi ve direkt üriner sistem grafsi incelemeleri yapılmıştır.

Bulgular
Çalışmaya dahil edilen 168 hastanın 99'u (%58,9) erkek ve 69'u (%41,1) kadını ve yaş ortalamaları 47,3 (±17,2) olarak bulundu. M-AAM sorgulama formunun iç tutarlılığının bir ölçüsü olan Cronbach alfa değeri 0,92 olarak hesaplandı. Test-Tekar test tutarlılığı hesaplandığında toplam skor için Spearman korelasyon katsayısı r=0,98 (p=0,001) olarak bulundu. Kesme değeri 12,5 olarak alındığında M-AAM’nin AAM tanısı koymadaki en yüksek sensitivite ve spesifite değerleri elde edilmektedir, sırasıyla %97 ve %94’tür.

Sonuç

Anahtar Kelimeler
Aşırı aktif mesane, sorgulama formu, validasyon, yaşam kalitesi

Correspondence
Naşide Mangır MD, Marmara University Facult of Medicine, Urology, İstanbul, Turkey
E-mail: info@tufantarcan.com
Journal of Urological Surgery.
Introduction

Overactive Bladder (OAB) was first described by Abrams et al. in 1997 (1) and in 2002 it was defined by International Continence Society (ICS) as "urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of pathologic or metabolic conditions that might explain these symptoms" (2). OAB is a chronic disease with a prevalence of 12.4-53.1% (3,4,5) and it is associated with decreased quality of life and high health care costs (6).

In clinical practice the diagnosis of OAB is a clinical diagnosis that involves elimination of other causes and relies mainly on the symptoms of patients instead of objective findings such as urodynamic diagnosis. This necessitates the use of patient reported outcome measurement tools such as symptom questionnaires in diagnosis and management of OAB syndrome (7). A variety of questionnaires has been devised for use in patients with urinary incontinence (8) but the only symptom questionnaire specific for OAB is OAB-q questionnaire that was constituted in English language in 2002 (9).

The linguistically validated Turkish version of OAB-V8 questionnaire that involves the first 8 questions of the original OAB form is being used since 2006 in our country (10). The reliability analysis of this form was also performed by our group recently (11). Although the currently used Turkish version of OAB-V8 questionnaire is the best available symptom assessment tool to be used in patients with OAB, it does not allow us to question the quality of life and sexual effects of the disease. Also our experiences with the use of this form during daily clinical practice in our clinic has suggested that it could be possible to further modify this form to meet the specific needs of our society. For example we have changed the expression "frequent voiding during daytime" as "going to toilet more than 8 times during daytime" or similarly "a disturbing sense of urgency", "a sudden/ unexpected sense of urgency" and "an uncontrollable desire to void" was questioned with a single question in our form as "going to toilet with a sudden sense of urgency". Likewise we have asked the original "nocturia" and "waking up during night to go to urinate" in a single question "waking up with a sense to urinate and going to toilet" in our form.

The aim of this study is to constitute and validate a symptom questionnaire to be used in the diagnosis and follow up of patients with OAB that complies with the specific needs of the Turkish society and that allows the assessment of both disease symptoms and their effects on quality of life.

Materials and Methods

Constitution of Marmara Overactive Bladder (M-OAB) Questionnaire

All the existing questionnaires for OAB, urinary incontinence and pelvic floor diseases were reviewed. The need for a specific questionnaire that can be used to improve the diagnosis, symptom and quality of life effects evaluation of OAB was established. A set of questions from our clinical experiences were listed and these were simplified after one- to one interviews with patients and target group studies. During these procedures the specific phrases and concepts that are better perceived and most comfortably used by the patients were determined. As a result 8 questions that inquire about the symptoms of OAB and their effects on quality of life were established. An analog scale that allows the patient to grade the severity of his/her urgency which is the most important symptom of OAB, was included at the end of the questionnaire. The validation studies of the constituted M-OAB questionnaire was initiated afterwards.

The Validation Studies of Marmara Overactive Bladder (M-OAB) Questionnaire

A total of 78 OAB patients and 90 control patients were included in this study between January 2007 and June 2007. All included patients underwent urine analysis/ culture, blood creatinine levels, 3- day voiding dairy, urinary ultrasonography and plain abdominal graphy evaluations. The diagnosis of OAB was a clinical diagnosis based on history, urine flow- chart, laboratory and radiological findings.

Patients completed the M-OAB questionnaire 2 times with 2 weeks interval between the evaluations. The questionnaire consisted of 8 questions each of which evaluated the symptom severity graded by the patients as not at all (0), mild (1), moderate (2), severe (3) and extremely severe (4) and an analog scale that allows grading the severity of the symptom "urgency". Total score ranged between a minimum of 0+0 and a maximum of 32+ 10.

The analysis of validation was performed using SPSS v15.0 software. Internal consistency was evaluated by Cronbach alpha value and test-retest analysis. The cut off value was calculated by the ROC analysis.

Results

Among 168 patients included 99 (58.95%) were males and 69 (41.1%) were females. The mean age was 47.3 (±17.2) years.

The mean M-OAB scores of OAB and control patients are shown in Table 1. The mean M-OAB scores of OAB patients and control patients were 19.5±6.2 and 4.1±3.2, respectively (p=0.001). The OAB patients included in the study were wet OAB in 30.8% (n=24) and dry OAB in 69.2% (n=54).

The Cronbach alpha value which is a determinant of internal consistency was 0.92 for M-OAB questionnaire (Table 2). This value was higher than the recommended value of 0.7. The correlation of each question with the other questions were shown in Table 3.

Among all questions and the analog scale the strongest correlation with the total score was observed for the questions 5, 6 and 7 (Table 2). The Spearman correlation co-efficient for total score was found to be 0.98 (p= 0.001) in the test- retest analysis (Figure 1). When the questions were evaluated individually the ones with the highest consistency were questions 1 (r=0.96), 3 (r=0.95), 5 (r=0.95) and 6 (r=0.95). The question that has the lowest test- retest consistency was the question 8 with a Spearman rho value of 0.83.

The ROC analysis used to determine the cut off value of the total M-OAB score that would give the highest sensitivity and specificity values is shown in Table 4. The ROC curve used to calculate the cut- off point is shown in Figure 2. The highest sensitivity (97%) and specificity (94%) values for the M-OAB questionnaire to make a diagnosis of OAB were obtained with a cut off value of 12.5 for the total score (Table 4).

Table 1. The mean Marmara Overactive Bladder (M-OAB) total scores and Analog scale scores of patients with and without overactive bladder

<table>
<thead>
<tr>
<th></th>
<th>Patients with OAB (n=78)</th>
<th>Patients without OAB (n=90)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>M-OAB score</td>
<td>19.5±6.2</td>
<td>4.2±3.2</td>
<td>0.001</td>
</tr>
<tr>
<td>Analog Scale</td>
<td>6.9±2.5</td>
<td>2.1±1.5</td>
<td>0.001</td>
</tr>
</tbody>
</table>
The correlation between the analog scale and the total score of the first 8 questions was found to be high with a Spearman rho correlation coefficient of 0.79 \( (p=0.001) \) (Figure 3).

**Discussion**

M-OAB symptom questionnaire is developed both as a symptom and a basic quality of life assessment questionnaire. It can be deduced that our questionnaire consists of 3 parts: first 4 questions mentioning disease symptoms, last 4 questions measuring quality of life and the analog scale that grades the severity of urgency which is the main symptom of OAB (Figure 4).

Compared to OAB-V8 the newly presented M-OAB questionnaire provides the clinicians with 3 main advantages: 1) It allows the assessment of quality of life, 2) With use of the analog scale, it allows precise evaluation of how exactly the urgency is experienced by the patient 3) It allows basic evaluation of effects of OAB on sexual functions of the patient. In addition to these, based on our initial experiences related to the use of the questionnaire we observed that this form can be better perceived by Turkish population compared to the OAB-V8 form although there are not any studies on direct comparisons of the two forms. The main restriction of using M-OAB questionnaire can be that it will not be able to allow standardization in the literature initially. For this reason we suggest that it will be plausible to use both M-OAB and the validated Turkish version of OAB-V8 until the M-OAB questionnaire gains more widespread acceptance.

---

<table>
<thead>
<tr>
<th>Question</th>
<th>Corrected Question-Total score correlation</th>
<th>The Cronbach alpha value when the question is eliminated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Question 1</td>
<td>.725</td>
<td>.906</td>
</tr>
<tr>
<td>Question 2</td>
<td>.657</td>
<td>.911</td>
</tr>
<tr>
<td>Question 3</td>
<td>.784</td>
<td>.904</td>
</tr>
<tr>
<td>Question 4</td>
<td>.663</td>
<td>.911</td>
</tr>
<tr>
<td>Question 5</td>
<td>.876</td>
<td>.897</td>
</tr>
<tr>
<td>Question 6</td>
<td>.837</td>
<td>.901</td>
</tr>
<tr>
<td>Question 7</td>
<td>.858</td>
<td>.898</td>
</tr>
<tr>
<td>Question 8</td>
<td>.572</td>
<td>.915</td>
</tr>
<tr>
<td>Analog Scale</td>
<td>.821</td>
<td>.923</td>
</tr>
</tbody>
</table>

**Table 3. The correlation of each question of the Marmara Overactive Bladder (M-OAB) questionnaire with other questions**

<table>
<thead>
<tr>
<th>Question</th>
<th>Question 1</th>
<th>Question 2</th>
<th>Question 3</th>
<th>Question 4</th>
<th>Question 5</th>
<th>Question 6</th>
<th>Question 7</th>
<th>Question 8</th>
<th>Analog scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Question 1</td>
<td>1.000</td>
<td>.656</td>
<td>.646</td>
<td>.408</td>
<td>.659</td>
<td>.589</td>
<td>.669</td>
<td>.442</td>
<td>.649</td>
</tr>
<tr>
<td>Question 2</td>
<td>.656</td>
<td>1.000</td>
<td>.587</td>
<td>.407</td>
<td>.602</td>
<td>.565</td>
<td>.576</td>
<td>.370</td>
<td>.566</td>
</tr>
<tr>
<td>Question 3</td>
<td>.646</td>
<td>.587</td>
<td>1.000</td>
<td>.552</td>
<td>.697</td>
<td>.658</td>
<td>.700</td>
<td>.408</td>
<td>.749</td>
</tr>
<tr>
<td>Question 4</td>
<td>.408</td>
<td>.407</td>
<td>.552</td>
<td>1.000</td>
<td>.657</td>
<td>.633</td>
<td>.634</td>
<td>.420</td>
<td>.616</td>
</tr>
<tr>
<td>Question 5</td>
<td>.659</td>
<td>.602</td>
<td>.697</td>
<td>.657</td>
<td>1.000</td>
<td>.849</td>
<td>.837</td>
<td>.525</td>
<td>.770</td>
</tr>
<tr>
<td>Question 6</td>
<td>.589</td>
<td>.565</td>
<td>.658</td>
<td>.633</td>
<td>.849</td>
<td>1.000</td>
<td>.842</td>
<td>.582</td>
<td>.700</td>
</tr>
<tr>
<td>Question 7</td>
<td>.669</td>
<td>.576</td>
<td>.700</td>
<td>.634</td>
<td>.837</td>
<td>.842</td>
<td>1.000</td>
<td>.546</td>
<td>.726</td>
</tr>
<tr>
<td>Question 8</td>
<td>.442</td>
<td>.370</td>
<td>.408</td>
<td>.420</td>
<td>.525</td>
<td>.582</td>
<td>.546</td>
<td>1.000</td>
<td>.511</td>
</tr>
<tr>
<td>Analog scale</td>
<td>.649</td>
<td>.566</td>
<td>.749</td>
<td>.616</td>
<td>.770</td>
<td>.700</td>
<td>.726</td>
<td>.511</td>
<td>1.000</td>
</tr>
</tbody>
</table>
surprising and also with this correlation evident it can be suggested that analog scale alone can be used as a quick monitoring tool. The lowest consistency in test-retest analysis was evident for question 8 which inquires about sexual health effects of OAB which may be related to the inherent difficulties in assessment of sexual symptoms/behaviours.

The cut-off value we suggest for total score 12. This value as seen in the ROC curve has the highest sensitivity and specificity to distinguish between OAB and healthy patients.

**Conclusion**

This study shows the development of a reliable and valid OAB specific symptom and quality of assessment tool that is short and easily applicable in the daily clinical practice. This questionnaire can provide the clinicians with practical comfort and a standardized quantification of the patient symptoms. It is also presented to the attention of the international scientific community to be considered for further validations in other languages which can allow a more standardized reporting.

**References**